Lukas Biomedical Inc. (TPEX:6814)

Market Cap	977.77M +5.7%
Revenue (ttm)	179.49M -5.4%
Net Income	-85.63M
EPS	-2.05
Shares Out	41.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,472
Open	23.10
Previous Close	23.10
Day's Range	23.00 - 24.20
52-Week Range	21.00 - 32.50
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Lukas Biomedical

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 87
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6814

Financial Performance

In 2025, Lukas Biomedical's revenue was 179.49 million, a decrease of -5.44% compared to the previous year's 189.83 million. Losses were -85.63 million, -9.27% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error